Legend Biotech Corporation (FRA:9LB)
Germany · Delayed Price · Currency is EUR 16.50
-3.10 (-15.82%)
Last updated: Jul 28, 2026, 6:00 PM CET
Legend Biotech Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 646.4 | 901.9 | 286.7 | 1,278 | 786.03 | 688.94 |
Short-Term Investments | 188.2 | 46.7 | 835.9 | 31 | 239.62 | 193.46 |
Cash & Short-Term Investments | 834.6 | 948.6 | 1,123 | 1,309 | 1,026 | 882.4 |
Cash Growth | -16.99% | -15.50% | -14.22% | 27.60% | 16.23% | 74.49% |
Accounts Receivable | 1.7 | 13.1 | 6.4 | 100.04 | 0.09 | 50.41 |
Total Trade Receivables | 1.7 | 13.1 | 6.4 | 100.04 | 0.09 | 50.41 |
Inventory | 37.1 | 32 | 23.9 | 19.43 | 10.35 | 1.75 |
Other Current Assets | 209.3 | 253.4 | 131 | 69.61 | 63.03 | 15.3 |
Total Current Assets | 1,083 | 1,247 | 1,284 | 1,498 | 1,099 | 949.85 |
Net Property, Plant & Equipment | 452.5 | 401.5 | 201.2 | 189.68 | 161.67 | 142.96 |
Other Intangible Assets | - | - | - | 4.06 | 3.41 | 4.68 |
Long-Term Investments | - | - | - | 4.36 | - | 4.71 |
Other Long-Term Assets | 61.5 | 85.1 | 185.1 | 152.71 | 66.76 | 17.27 |
Total Assets | 1,597 | 1,734 | 1,670 | 1,849 | 1,331 | 1,119 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accounts Payable | 74.3 | 83 | 38.6 | 30.66 | 32.89 | 7.04 |
Accrued Expenses | 130.2 | 195.4 | 166.2 | 122.31 | 184.11 | 123.56 |
Current Portion of Leases | 11.2 | 7.4 | 4.8 | 3.18 | 3.56 | 0.91 |
Unearned Revenue | 6 | 11.3 | 46.9 | 53.01 | - | - |
Other Current Liabilities | 287.4 | 339.3 | 21.2 | 7.27 | 77.22 | 97.69 |
Total Current Liabilities | 509.1 | 636.4 | 277.7 | 216.42 | 297.79 | 229.2 |
Long-Term Leases | 112.1 | 87.2 | 44.6 | 44.17 | 20.04 | 1.59 |
Other Long-Term Liabilities | 7.8 | 8 | 307.3 | 336.65 | 268.82 | 122.72 |
Total Long-Term Liabilities | 119.9 | 95.2 | 351.9 | 380.82 | 288.86 | 124.32 |
Total Liabilities | 629 | 731.6 | 629.6 | 597.24 | 586.65 | 353.52 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 0.1 | 0.1 | 0.1 | 0.04 | 0.03 | 0.03 |
Additional Paid-in Capital | 967.6 | 1,002 | 1,041 | 1,251 | 744.28 | 765.91 |
Shareholders' Equity | 967.7 | 1,002 | 1,041 | 1,251 | 744.31 | 765.94 |
Total Liabilities & Equity | 1,597 | 1,734 | 1,670 | 1,849 | 1,331 | 1,119 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 123.3 | 94.6 | 49.4 | 47.34 | 23.6 | 2.5 |
Net Cash (Debt) | 711.3 | 854 | 1,073 | 1,261 | 1,002 | 879.89 |
Net Cash Growth | -24.99% | -20.42% | -14.92% | 25.88% | 13.88% | 75.17% |
Net Cash Per Share | 3.85 | 4.63 | 5.87 | 7.16 | 6.30 | 6.25 |
Book Value | 967.7 | 1,002 | 1,041 | 1,251 | 744.31 | 765.94 |
Book Value Per Share | 5.24 | 5.44 | 5.69 | 7.11 | 4.68 | 5.44 |
Tangible Book Value | 967.7 | 1,002 | 1,041 | 1,247 | 740.9 | 761.26 |
Tangible Book Value Per Share | 5.24 | 5.44 | 5.69 | 7.08 | 4.66 | 5.40 |